A subscription to JoVE is required to view this content. Sign in or start your free trial.
Here, we describe the methodology to knock out a gene of interest in the immune system using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease (Cas9)-based technologies and the evaluation of these mice in a cluster of differentiation 40 (CD40) agonistic antibody-induced colitis model.
The immune system functions to defend humans against foreign invaders such as bacteria and viruses. However, disorders of the immune system may lead to autoimmunity, inflammatory disease, and cancer. The inflammatory bowel diseases (IBD)-Crohn's disease (CD) and ulcerative colitis (UC)-are chronic diseases marked by relapsing intestinal inflammation. Although IBD is most prevalent in Western countries (1 in 1,000), incident rates are increasing around the world. Through association studies, researchers have linked hundreds of genes to the pathology of IBD. However, the elaborate pathology behind IBD and the high number of potential genes pose significant challenges in finding the best therapeutic targets. Additionally, the tools needed to functionally characterize each genetic association introduce many rate-limiting factors such as the generation of genetically modified mice for each gene. To investigate the therapeutic potential of target genes, a model system has been developed using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease (Cas9)-based technologies and a cluster of differentiation 40 (CD40) agonistic antibody. The present study shows that CRISPR/Cas9-mediated editing in the immune system can be used to investigate the impact of genes in vivo. Limited to the hematopoietic compartment, this approach reliably edits the resulting reconstituted immune system. CRISPR/Cas9-edited mice are generated faster and are far less expensive than traditional genetically modified mice. Furthermore, CRISPR/Cas9 editing of mice has significant scientific advantages compared to generating and breeding genetically modified mice such as the ability to evaluate targets that are embryonic lethal. Using CD40 as a model target in the CD40 agonistic antibody-induced colitis model, this study demonstrates the feasibility of this approach.
Autoimmune diseases refer to conditions in which a patient's immune system attacks their own cells and organs, resulting in chronic inflammation and tissue damage. Nearly 100 different types of autoimmune conditions have been described to date, affecting 3-5% of the human population1. Many of the autoimmune conditions, including systemic lupus erythematosus and IBD, lack effective treatments and present significant unmet medical needs. Currently affecting around 1.5 million people in the USA alone, IBD is a devastating disease marked by progressive, persistent, and relapsing intestinal inflammation with no available cure. Unraveling the und....
All animal experiments performed following this protocol must be approved by the respective Institutional Animal Care and Use Committee (IACUC). All procedures described here were approved by the AbbVie IACUC.
1. Generation of required lentiviruses and procurement of donor and recipient animals
NOTE: The Table of Materials includes source and order number details for all animals, instruments, and reagents used in this protocol.
Following the procedure described above, mice expressing CD40-targeted gRNA were generated. By week 2, B-cells, CD11b+ macrophages, and CD11c+ dendritic cells (DCs) were engrafted (Figure 2). T-cells however, as expected based on previous literature18, took longer to fully engraft and required 12 weeks post-engraftment to reach ~90% (Figure 2). Immune organs, such as the spleen and lymph nodes, had the mos.......
The results shown here introduce a novel CRISPR/Cas9-based genome editing platform capable of investigating gene function in this CD40 agonistic antibody-induced colitis model. Cell sorting enriched the pool of genetically modified LSK cells, resulting in over 90% reduction in CD40 expression within the reconstituted animals-in just 4 months. Furthermore, the reduced expression of CD40 within the immune system had a profound effect within the CD40 agonistic antibody-induced colitis model, significantly reducing disease e.......
Thank you to Ruoqi Peng, Donna McCarthy, Jamie Erikson, Liz O'Connor, Robert Dunstan, Susan Westmoreland, and Tariq Ghayur for your efforts supporting this work. Thank you to Pharmacology leaders including Rajesh Kamath and others for their leadership in establishing the CD40 agonistic antibody-induced colitis model in WT C57Bl/6 mice. Additionally, thank you to all those at AbbVie Bioresearch Center and Cambridge Research Center in the Comparative Medicine East Department supporting in vivo experiments.
We would like to thank the Zhang lab from the Broad Institute and McGovern Institute of Brain Research at the Massachusetts Institute ....
Name | Company | Catalog Number | Comments |
6-well tissue culture plates | Corning/Costar | #3506 | |
TransIT-LT1 | Mirus Bio | MIR 2300/5/6 | |
MACS Buffer (autoMACS Running Buffer) | Miltenyi Biotec | 130-091-221 | |
0.45 µm filter unit | Millipore | #SLHV013SL | |
0.6 mL microcentrifuge Tube | Axygen | MCT-060-C-S | |
1.5 mL Eppendorf Tube | Axygen | MCT-150-C-S | |
15mL Conical | VWR | 21008-918 | |
23 G Needle | VWR | #305145 | |
24 Well Non-TC Plates | Falcon | #351147 | |
24-Well TC Plates | Falcon | #353047 | |
50 mL Conical tube | VWR | 21008-951 | |
5 mL Syringe | BD Biosciences | #309647 | |
70 µm Filter | Miltenyi | #130-098-462 | |
96-Well Flat Bottom Plates | Corning | #3599 | |
96-Well U-Bottom Plates | Corning/Costar | #3365 | |
Anesthesia Machine | VetEquip - COMPAC5 | #901812 | |
Anti-CD40 Agonist monoclonal antibody | BioXcell | BE-0016 | |
Anti-p40 monoclonal antibody | BioXcell | BE-0051 | |
B220 PE Antibody | BioLegend | #103208 | |
Bovine serum albumin | Sigma Aldrich | A7906-100G | |
Cas9 Knock-in Mice | Jackson Labs | #026179 | C57Bl/6 background |
CD117+ Beads | Miltenyi | #130-091-224 | |
CD11b PE Antibody | BioLegend | #101208 | |
CD3 PE Antibody | BD Biosciences | #553240 | |
Centrifuge | Beckman Coulter | Allegra 6KR Centrifuge | |
Countertop Centrifuge | Eppendorf | Centrifuge 5424 | |
DPBS | ThermoFisher | #14190136 | |
Dulbecco’s Modified Eagle Medium | Mediatech | #10-013-CV | |
Ethylenediamine tetraacetic acid (EDTA) | Invitrogen | AM9260G | |
Endoscope | Karl Storz | N/A | Custom Coloview Tower |
Flow cytometer | BD Biosciences | FACS Aria II | |
Fms-related tyrosine kinase 3 ligand (Flt-L) | PeproTech | #250-31L | |
Gr-1 PE Antibody | BD Biosciences | #553128 | |
Hank's balanced salt solution (HBSS) | ThermoFisher | #14170120 | |
Heat-Inactivated Fetal Bovine Serum | HyClone | #SH30071.03 | |
IL-7 | PeproTech | #217-17 | |
Incubator | Binder | #9040-0116 | |
Isoflurane | HenrySchein | #6679401710 | |
LS Column | Miltenyi | #130-042-041 | |
Ly5.1 Pepboy Mice | Jackson Labs | #002014 | C57Bl/6 background |
mouse stem cell factor (mSCF) | PeproTech | #250-03 | |
Sodium chloride (NaCl) | Hospira | #00409488850 | |
OPTI-MEM serum-free media | Invitrogen | #31985-070 | |
Penicillin-streptomycin (PenStrep) | ThermoFisher | #15140-122 | |
Plate Shaker | ThermoFisher | #88880023 | |
pLentiPuro | Addgene | #52963 | |
Polybrene (10 µg/µL) | Sigma Aldrich | #TR-1003-G | |
Red Blood Cell Lysis Buffer | eBioscience | #00-4333 | |
Retronectin | Takarbio | #T100B | |
Sca-1 APC Antibody | BioLegend | #108112 | |
StemSpan | StemCell Technologies | #09600 | |
Ter119 PE Antibody | eBioscience | #12-5921 | |
Thrombopoietin (TPO) | PeproTech | #315-14 | |
X-ray Irradiator | Precision X-Ray | X-Rad 320 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved